BridgeBio Pharma (BBIO) Net Cash Flow Growth (1y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 198.34% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 467.41% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14,223.53% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 453.08% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -125.22% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 53.46% |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | 320.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 320.55% |
| Dec 31, 2025 | -126.49% |
| Sep 30, 2025 | 25.16% |
| Jun 30, 2025 | 189.33% |
| Mar 31, 2025 | -269.76% |
| Dec 31, 2024 | 312.79% |
| Sep 30, 2024 | -171.00% |
| Jun 30, 2024 | 165.19% |
| Mar 31, 2024 | 354.12% |
| Dec 31, 2023 | -87.82% |
| Sep 30, 2023 | 1,418.35% |
| Jun 30, 2023 | -212.20% |
| Mar 31, 2023 | 182.20% |
| Dec 31, 2022 | -132.30% |
| Sep 30, 2022 | 106.63% |
| Jun 30, 2022 | 206.27% |
| Mar 31, 2022 | -119.26% |
| Dec 31, 2021 | 2,548.19% |
| Sep 30, 2021 | -13.85% |
| Jun 30, 2021 | 57.13% |
| Mar 31, 2021 | -70.73% |
| Dec 31, 2020 | 82.65% |
| Sep 30, 2020 | -244.75% |
| Jun 30, 2020 | -174.28% |
| Mar 31, 2020 | 722.09% |
| Dec 31, 2019 | -122.39% |
| Sep 30, 2019 | 395.59% |